ClinConnect ClinConnect Logo
Search / Trial NCT06210555

Multiparametric MRI in a Prospective Cohort of Living Kidney Donors, Recipients, and Healthy Controls: Correlations With Markers of Renal Function, Fibrosis and Ageing

Launched by PATRICK SCHJELDERUP · Jan 8, 2024

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying a new way to look at kidney health using a type of imaging called multiparametric MRI (mpMRI). Currently, the only way to diagnose kidney damage, specifically a condition called renal fibrosis, is through an invasive procedure known as a kidney biopsy, which can be uncomfortable and may not always give a complete picture. The researchers believe that mpMRI can provide important information about kidney structure and function without the need for surgery. This study will compare the results from the mpMRI scans to traditional methods for measuring kidney function and damage over a two-year period in living kidney donors, transplant recipients, and healthy individuals.

To participate, you should be a living kidney donor or recipient who is able to undergo an MRI scan. Healthy volunteers are also welcome if they meet certain health criteria, such as having normal blood pressure and kidney function. Participants can expect to have mpMRI scans taken periodically, and the researchers will monitor how these results relate to kidney function over time. This trial aims to improve how we assess kidney health and could lead to safer, non-invasive methods for diagnosing kidney problems in the future.

Gender

ALL

Eligibility criteria

  • Living kidney donors and transplant recipients:
  • Inclusion Criteria:
  • Approved as a living kidney donor or recipient of a kidney from a living donor.
  • Able to cooperate to an MRI examination
  • Exclusion Criteria:
  • Contraindications to MRI due to incompatible foreign objects.
  • Severe claustrophobia
  • Healthy controls:
  • Inclusion Criteria:
  • Office BP \< 140/90 mmHg. (use of 1 antihypertensive drug allowed)
  • Normal eGFR. (CKD-EPI)
  • Urine albumin-to-creatinine ratio \< 30 mg/g.
  • Dipstick negative for hematuria and proteinuria.
  • Able to cooperate to an MRI examination.
  • Exclusion Criteria:
  • Contraindications to MRI due to incompatible foreign objects.
  • Severe claustrophobia.
  • Pregnancy.
  • Condition(s) that would exclude living kidney donation.

About Patrick Schjelderup

Patrick Schjelderup is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With extensive experience in managing and overseeing clinical studies, he emphasizes rigorous adherence to regulatory standards and ethical practices. His collaborative approach fosters partnerships with research institutions and healthcare professionals, ensuring that trials are designed to meet the highest scientific and operational standards. Patrick's focus on innovative therapeutic solutions underscores his dedication to addressing unmet medical needs and enhancing the quality of care in diverse patient populations.

Locations

Aarhus, Central Denmark Region, Denmark

Aalborg, North Jutland Region, Denmark

Patients applied

0 patients applied

Trial Officials

Patrick Schjelderup, MD

Principal Investigator

Aalborg University Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported